跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 20,230 条关于
“anti-MuSK”
全部
20,230
临床试验
10,532
药物
3,711
机构
83
资讯
5,904
10个月前
Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis
去年
Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment
2年前
Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis
去年
NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment
去年
Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies
去年
VYVGART Achieves Primary Endpoint in Phase 3 Trial for AChR-Ab Seronegative Myasthenia Gravis
9个月前
FDA Approves UPLIZNA as First CD19-Targeted B Cell Therapy for Generalized Myasthenia Gravis
8个月前
Neuralink Expands Human Trials to 21 Participants as Musk Announces Next-Generation Brain Implant
去年
FcRn Inhibitors Show Promise in Autoimmune Disease Treatment, Market Set for Growth
去年
Cabaletta Bio to Present New CABA-201 Clinical Data at ACR Convergence 2024
第 1 页,共 591 页
上一页
下一页